GH Research (GHRS) Consolidated Net Income (2020 - 2025)
GH Research's (GHRS) quarterly Consolidated Net Income came in at -$13.6 million in Q4 2025, down 5.01% year-on-year from -$14.3 million in Q4 2024, and up 3.29% quarter-over-quarter from -$14.1 million in Q3 2025.
GH Research (GHRS) Consolidated Net Income (2020 - 2025) Analysis & Trends
GH Research's Consolidated Net Income history runs 6 years deep, the most recent figure standing at -$13.6 million for Q4 2025.
- On a quarterly basis, Consolidated Net Income fell 5.01% year-over-year to -$13.6 million in Q4 2025; TTM through Dec 2025 was -$46.8 million, a 8.26% decrease from a year earlier, with the FY2025 full-year figure at -$46.8 million, down 8.26% from the prior year.
- Consolidated Net Income advanced to -$13.6 million in Q4 2025 per GHRS's latest filing, from -$14.1 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$1.4 million in Q1 2021 and bottomed at -$14.1 million in Q3 2025.
- The 5-year median for Consolidated Net Income is -$8.0 million (2022), against an average of -$8.3 million.
- Across the five-year window, Consolidated Net Income sank 10304.44% in 2021 and increased 22.53% in 2023, its largest moves.
- Year by year, Consolidated Net Income stood at -$6.7 million in 2021, then declined by 19.19% to -$7.9 million in 2022, then increased by 22.53% to -$6.1 million in 2023, then slumped by 110.89% to -$13.0 million in 2024, then fell by 5.01% to -$13.6 million in 2025.
- Per Business Quant, the three latest GHRS Consolidated Net Income figures stand at -$13.6 million (Q4 2025), -$14.1 million (Q3 2025), and -$8.8 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | GH Research | 1.65 Bn | 1.65 Bn | - | -13.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -13.62 Mn |
| Sep 30, 2025 | -14.08 Mn |
| Jun 30, 2025 | -8.83 Mn |
| Mar 31, 2025 | -10.28 Mn |
| Dec 31, 2024 | -12.97 Mn |
| Sep 30, 2024 | -10.49 Mn |
| Jun 30, 2024 | -10.83 Mn |
| Mar 31, 2024 | -8.96 Mn |
| Dec 31, 2023 | -6.15 Mn |
| Sep 30, 2023 | -7.43 Mn |
| Jun 30, 2023 | -7.79 Mn |
| Mar 31, 2023 | -9.26 Mn |
| Dec 31, 2022 | -7.94 Mn |
| Sep 30, 2022 | -6.91 Mn |
| Jun 30, 2022 | -6.72 Mn |
| Mar 31, 2022 | -8.02 Mn |
| Dec 31, 2021 | -6.66 Mn |
| Sep 30, 2021 | -4.68 Mn |
| Jun 30, 2021 | -2.61 Mn |
| Mar 31, 2021 | -1.35 Mn |